Photobiomodulation therapy for acute radiodermatitisRobijns, Joliena,b; Lodewijckx, Joya,b; Mebis, Jeroena,b,cCurrent Opinion in Oncology: February 8, 2019 - Volume Publish Ahead of Print - Issue - p doi: 10.1097/CCO.0000000000000511 REVIEW: PDF Only Buy PAP Abstract Author InformationAuthors Article MetricsMetrics Purpose of review The number of clinical trials on the use of photobiomodulation therapy (PBMT) for the management of cancer therapy-related complications is growing steadily. One of the side-effects that is under investigation is acute radiodermatitis (ARD), an inflammatory skin reaction caused by radiotherapy. In this review, an overview is given on the state of art of the application of PBMT for the prevention and management of ARD. Recent findings Up to now about seven clinical trials have been performed, investigating the use of PBMT in the prevention and/or management of ARD. Results demonstrate that PBMT can effectively reduce the incidence of severe ARD, decrease the accompanying pain, and improve the patients’ quality of life. Moreover, the technique seems to be well tolerated in oncologic patients. Summary On the basis of the available evidence, there could be a strong recommendation to use PBMT in the prevention and management of ARD in cancer patients. aFaculty of Medicine & Life Sciences, Hasselt University bLimburg Oncology Center cDepartment of Medical Oncology, Jessa Hospital, Hasselt, Belgium Correspondence to Dr Jolien Robijns, MSc, PhD, Faculty of Medicine & Life Sciences, Hasselt University, Martelarenlaan 42, 3500 Hasselt, Belgium. Tel. +32 1133 7229;. e-mail: Jolien.email@example.com Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.